Drugs / Varicella vaccine
Varicella vaccine
Trials 14
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Sinovac Biotech Co., Ltd | Results 首次量化第2剂额外保护效果 科兴水痘疫苗真实世界研究发表于《Vaccines》 sinovac.com ↗
结果提示，第2剂在本研究约3年的观察期内持续显示出额外保护获益。 |
| 2025-10-25 | Sinovac Biotech Co., Ltd | Results 科兴水痘疫苗安全性更优 国际学术期刊《疫苗》发表最新研究 sinovac.com ↗
研究结果显示科兴水痘减毒活疫苗免疫原性达到非劣效性标准，且安全性优于对照疫苗。 |
| 2024-06-18 | Sinovac Biotech Co., Ltd | Regulatory SINOVAC科兴水痘疫苗12岁以上人群扩龄获批 sinovac.com ↗ |
| 2023-03-06 | Merck Sharp & Dohme LLC | Regulatory US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗
With these approvals, healthcare professionals now have the option to choose to administer all routinely recommended injectable pediatric vaccinations included in the CDC immunization schedule, via the same IM route. |
| 2023-01-09 | Sinovac Biotech Co., Ltd | Results 1岁儿童同时接种科兴甲肝灭活疫苗和水痘减毒活疫苗具有良好安全性和免疫原性 sinovac.com ↗
研究结果显示，同时接种两种疫苗安全性和免疫原性良好，儿童1岁龄可以同时接种水痘减毒活疫苗和甲肝灭活疫苗。 |
| 2022-06-10 | Sinovac Biotech Co., Ltd | Results 最新研究表明SINOVAC科兴水痘减毒活疫苗单剂接种的免疫持久性、加强免疫的免疫原性和安全性良好 sinovac.com ↗
研究结果显示，接种单剂SINOVAC科兴水痘减毒活疫苗具有良好的免疫持久性，完成第二剂次接种后抗体阳性率 高达100% ，且疫苗具有良好的安全性。 |
| 2019-12-29 | Sinovac Biotech Co., Ltd | Regulatory 科兴水痘减毒活疫苗获药品注册批件 sinovac.com ↗
2019年12月18日，科兴（大连）疫苗技术有限公司自主研发的预防用生物制品——水痘减毒活疫苗生产注册申请获 国家药品监督管理局（NMPA） 批准，取得药品注册批件。 |
| 2019-12-11 | SK Bioscience Co., Ltd. | Regulatory SK bioscience’s Varicella Vaccine Obtains World’s 2nd WHO PQ Certification skbioscience.com ↗
SK bioscience announced on the 11th that the company has obtained the WHO PQ certification for its varicella vaccine, ‘SKYVaricella®.´ |
| 2018-02-09 | Merck Sharp & Dohme LLC | Regulatory VARIVAX, Merck’s Varicella (Chickenpox) Vaccine, Awarded WHO Pre-Qualification Status merck.com ↗
VARIVAX ® (varicella virus vaccine live), the live attenuated varicella-zoster (VZV) vaccine from Merck & Co., Inc (known as MSD outside the U.S. and Canada) that helps prevent varicella (chickenpox) in individuals 12 months of age and older, has been awarded pre-qualification status by the World Health Organization (WHO). |
| 2013-09-04 | Merck Sharp & Dohme LLC | Regulatory Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk merck.com ↗
The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Merck’s overall global supply capabilities. |
All press releases naming this drug 10 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | varicella vaccine | “of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.” NCT01693380 ↗19“Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.” NCT05952505 ↗ “Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month” NCT01866566 ↗ “1 dose Varicella vaccine and 1 dose MMR given at the same time” NCT02146469 ↗ “Give the second varicella vaccine (a single 0.5 ml)” NCT02173899 ↗ “Varicella Vaccine” NCT06891872 ↗ |
| Known as | varicella live attenuated vaccine | “The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and...” NCT06987942 ↗ |
| Known as | VARIVAX | “varicella vaccine (VARIVAX)” NCT00213304 ↗ |
| Modality | Vaccine | “Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation” NCT00213304 ↗ |
| Route | Subcutaneous | “0.5 mL (single dose), Subcutaneous” NCT01190228 ↗ |